rel-Zotatifin

Overview

rel-Zotatifin is the racemic isomer of Zotatifin, acts as an eIF4A inhibitor with activity less than Zotatifin. Zotatifin (eFT226) is a potent, selective, and well-tolerated eIF4A inhibitor. Zotatifin promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5’-UTRs ( IC 50 =2 nM) and interferes with the assembly of the eIF4F initiation complex.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Eukaryotic Initiation Factor (eIF) | Products > Signaling Pathways > SARS-CoV | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-112163A
• CAS No.: 2098191-54-7
• Molecular Formula: C28H29N3O5
• Molecular Weight: 487.56
• Purity: 97.32%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 1.25 mg/mL (2.56 mM); Clear solution
• Availability: In-stock

Source

Original product source